دورية أكاديمية
Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019
| العنوان: | Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019 |
|---|---|
| المؤلفون: | Ji-Won Kim, Eun Jin Kim, Hyun Hee Kwon, Chi Young Jung, Kyung Chan Kim, Jung-Yoon Choe, Hyo-Lim Hong |
| المصدر: | The Korean Journal of Internal Medicine, Vol 36, Iss Suppl 1, Pp S253-S263 (2021) |
| بيانات النشر: | The Korean Association of Internal Medicine, 2021. |
| سنة النشر: | 2021 |
| المجموعة: | LCC:Medicine |
| مصطلحات موضوعية: | covid-19, severe acute respiratory syndrome coronavirus 2, lopinavir-ritonavir, hydroxychloroquine, Medicine |
| الوصف: | Background/Aims The efficacies of lopinavir-ritonavir or hydroxychloroquine remain to be determined in patients with coronavirus disease 2019 (COVID-19). To compare the virological and clinical responses to lopinavir-ritonavir and hydroxychloroquine treatment in COVID-19 patients. Methods This retrospective cohort study included patients with COVID-19 treated with lopinavir-ritonavir or hydroxychloroquine at a single center in Korea from February 17 to March 31, 2020. Patients treated with lopinavir-ritonavir and hydroxychloroquine concurrently and those treated with lopinavir-ritonavir or hydroxychloroquine for less than 7 days were excluded. Time to negative conversion of viral RNA, time to clinical improvement, and safety outcomes were assessed after 6 weeks of follow-up. Results Of 65 patients (mean age, 64.3 years; 25 men [38.5%]), 31 were treated with lopinavir-ritonavir and 34 were treated with hydroxychloroquine. The median duration of symptoms before treatment was 7 days and 26 patients (40%) required oxygen support at baseline. Patients treated with lopinavir-ritonavir had a significantly shorter time to negative conversion of viral RNA than those treated with hydroxychloroquine (median, 21 days vs. 28 days). Treatment with lopinavir-ritonavir (adjusted hazard ratio [aHR], 2.28; 95% confidence interval [CI], 1.24 to 4.21) and younger age (aHR, 2.64; 95% CI 1.43 to 4.87) was associated with negative conversion of viral RNA. There was no significant difference in time to clinical improvement between lopinavir-ritonavir- and hydroxychloroquine-treated patients (median, 18 days vs. 21 days). Lymphopenia and hyperbilirubinemia were more frequent in lopinavir-ritonavir-treated patients compared with hydroxychloroquine-treated patients. Conclusions Lopinavir-ritonavir was associated with more rapid viral clearance than hydroxychloroquine in mild to moderate COVID-19, despite comparable clinical responses. These findings should be confirmed in randomized, controlled trials. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1226-3303 2005-6648 |
| Relation: | http://www.kjim.org/upload/pdf/kjim-2020-224.pdf; https://doaj.org/toc/1226-3303; https://doaj.org/toc/2005-6648 |
| DOI: | 10.3904/kjim.2020.224 |
| URL الوصول: | https://doaj.org/article/e6c989c68fc44bfca7e8054e31b92e77 |
| رقم الأكسشن: | edsdoj.6c989c68fc44bfca7e8054e31b92e77 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 12263303 20056648 |
|---|---|
| DOI: | 10.3904/kjim.2020.224 |